$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How many times a day should I take gefitinib (Iressa)? What is the therapeutic effect of gefitinib
2025-10-19 11:44:20
Check Details
Sotoracib (AMG510) is now on the market~
2025-10-19 11:44:20
Check Details
Amg510 (sotorasiib) for the treatment of KRAS-G12C mutated non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Sotoracib (AMG510) is launched! Patient: High cost performance
2025-10-19 11:44:20
Check Details
Tepotinib, the world's first targeted drug for METex14 mutated lung cancer, was approved in Europe
2025-10-19 11:44:20
Check Details
The FDA announced that Rybrevant, the first targeted drug for lung cancer EGFR20ins, has been approved for marketing!
2025-10-19 11:44:20
Check Details
Where can I buy Rybrevant, a targeted therapy for lung cancer (NSCLC)? Are the side effects serious?
2025-10-19 11:44:20
Check Details
40 cigarettes a day can cause cerebral infarction! Smoking may cause these 3 serious diseases to come to you
2025-10-19 11:44:20
Check Details
Lumakras is approved in the United States to treat KRAS-G12C mutated non-small cell lung cancer (NSCLC)!
2025-10-19 11:44:20
Check Details
What is the medical insurance price of dacomitinib in 2022? Where can I buy it
2025-10-19 11:44:20
Check Details
The third generation ALK inhibitor—lorlatinib_Kangxule
2025-10-19 11:44:20
Check Details
How many times a day should I take lorlatinib? What are the adverse reactions of lorlatinib
2025-10-19 11:44:20
Check Details
1
2
...
3973
3974
3975
3976
3977
3978
3979
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
2
Vemurafenib (Zelboraf) Complete Medication Guide
3
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
4
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
5
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
6
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
7
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
8
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
9
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
10
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
11
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity
12
Complete Guide to Garsorasib Resistance Mechanisms and Follow-Up Treatments